Dapagliflozin is the most promising sodium-glucose cotransporter 2 (SGLT2) inhibitor candidate for canine cardiac disease, identified through pharmacology, safety, and pharmacokinetic review of regulatory documentation for empagliflozin, canagliflozin, and dapagliflozin in dogs.Journal of Vete…

The primary cardiac indication under investigation is myxomatous mitral valve disease (MMVD), the most prevalent cause of chronic heart failure in dogs.Journal of Vete… Standard-of-care with pimobendan and loop diuretics leaves MMVD with a poor prognosis due to its progressive nature, which is the clinical gap SGLT2 inhibitors are being evaluated to address.Journal of Vete… The parallels between canine MMVD and human chronic heart failure — for which dapagliflozin is already approved — form the translational rationale.Journal of Vete…

In healthy dogs, a single oral dose of dapagliflozin at 1.0 mg/kg produces both diuretic and ketogenic effects, supporting its potential decongestive and metabolic utility in heart failure.American Journa… Plasma ketone body concentrations became significantly higher at the 1.0 mg/kg dose compared to placebo beginning at 4 hours post-administration.American Journa… Under normal fasting conditions, canine plasma β-hydroxybutyrate is approximately 100 μmol/L (range 0–400 μmol/L); the concentration thought to confer myocardial metabolic benefit in prior work ranges from 500 to 3,000 μmol/L, though the threshold has not been established in dogs.American Journa… At 1.0 mg/kg, only 1 of 5 dogs exceeded 500 μmol/L, so whether this dose reliably achieves therapeutically relevant ketone concentrations in cardiac patients remains unresolved.American Journa…

The diuretic benefit of dapagliflozin in canine heart failure is uncertain. Whether glucosuria-driven osmotic diuresis translates into meaningful decongestion in dogs with heart failure has not been established, and the physiological response in cardiac patients may differ from healthy dogs due to altered renin-angiotensin-aldosterone system activation and differences in fluid distribution.American Journa…

A clinically relevant adverse effect at the 1.0 mg/kg dose is hyperchloremia. Plasma chloride concentrations were elevated at both the medium and high doses, though values remained within the reference range in healthy dogs.American Journa… The clinical significance of this finding in volume-overloaded cardiac patients — where acid-base and electrolyte balance are already perturbed — has not been evaluated.American Journa…

Enavogliflozin (DWP16001), another SGLT2 inhibitor, has been evaluated in diabetic and obese dogs. At 0.2 mg/kg it produced the most effective reductions in body condition score, body weight, body fat percentage, fat thickness, and chest and waist circumference in naturally obese dogs without affecting food consumption.BMC Veterinary… Its cardiac-specific effects in dogs have not been reported in the available veterinary literature.

Canagliflozin has been studied in insulin-treated diabetic dogs for its effect on interstitial glucose concentration, with cardiovascular comorbidities such as hypertension documented in dogs with spontaneous diabetes mellitus, though the clinical relevance of these comorbidities and the long-term renal and cardiovascular effects of SGLT2 inhibition in diabetic dogs remain unknown.Journal of Vete…

No canine-specific clinical trial data exist demonstrating that any SGLT2 inhibitor improves survival, reduces hospitalization, or slows disease progression in dogs with cardiac disease. The human evidence base — including FDA approval of dapagliflozin for heart failure with reduced ejection fraction independent of diabetes — provides the mechanistic and translational framework, but direct extrapolation of human doses and outcomes to dogs is not supported by current veterinary data.Journal of Vete…+2

Would you like a breakdown of the safety profile and known adverse effects of dapagliflozin specifically in dogs, including the dose ranges at which they occur?